ME01980B - Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat - Google Patents

Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat

Info

Publication number
ME01980B
ME01980B MEP-2014-150A MEP15014A ME01980B ME 01980 B ME01980 B ME 01980B ME P15014 A MEP15014 A ME P15014A ME 01980 B ME01980 B ME 01980B
Authority
ME
Montenegro
Prior art keywords
therapeutic compositions
tenofovir disoproxil
disoproxil fumarate
rilpivirine hcl
rilpivirine
Prior art date
Application number
MEP-2014-150A
Other languages
English (en)
French (fr)
Inventor
Reza Oliyai
Lauren Wiser
Mark Menning
Original Assignee
Gilead Sciences Inc
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01980(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc, Janssen Sciences Ireland Uc filed Critical Gilead Sciences Inc
Publication of ME01980B publication Critical patent/ME01980B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MEP-2014-150A 2010-11-19 2011-11-18 Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat ME01980B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41560010P 2010-11-19 2010-11-19
PCT/US2011/061515 WO2012068535A1 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EP11791161.0A EP2640362B2 (en) 2010-11-19 2011-11-18 Therapeutic compositions comprising rilpivirin hcl and tenovofir disoproxil fumarate

Publications (1)

Publication Number Publication Date
ME01980B true ME01980B (me) 2015-05-20

Family

ID=45094284

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2014-150A ME01980B (me) 2010-11-19 2011-11-18 Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat

Country Status (35)

Country Link
US (1) US10857102B2 (me)
EP (2) EP2640362B2 (me)
JP (2) JP2014500261A (me)
KR (1) KR101923103B1 (me)
CN (2) CN106511357A (me)
AP (1) AP3816A (me)
AR (2) AR084500A1 (me)
AU (3) AU2011329642B2 (me)
BR (1) BR112013012245B1 (me)
CA (1) CA2818097C (me)
CL (1) CL2013001402A1 (me)
CO (1) CO6761300A2 (me)
CR (1) CR20130293A (me)
DK (1) DK2640362T4 (me)
EA (2) EA201691695A1 (me)
EC (2) ECSP13012700A (me)
ES (1) ES2524408T5 (me)
HK (2) HK1190064A1 (me)
HR (1) HRP20140946T1 (me)
IL (1) IL226300B (me)
MA (1) MA34735B1 (me)
ME (1) ME01980B (me)
MX (1) MX347512B (me)
MY (1) MY185604A (me)
NZ (1) NZ610729A (me)
PE (3) PE20211657A1 (me)
PL (1) PL2640362T5 (me)
PT (1) PT2640362E (me)
RS (1) RS53691B1 (me)
SG (3) SG10201509521WA (me)
SM (1) SMT201400150B (me)
TW (1) TWI556840B (me)
UA (1) UA114075C2 (me)
WO (1) WO2012068535A1 (me)
ZA (1) ZA201304481B (me)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090053867A (ko) 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物
UY34262A (es) 2011-08-16 2013-04-05 Gilead Sciences Inc Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos
CA2779052A1 (en) * 2012-05-31 2013-11-30 Pharmascience Inc. Pharmaceutical composition of entecavir and process of manufacturing
UY35213A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
EP2832351A1 (en) * 2013-07-29 2015-02-04 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer Tablet Formulations Comprising Tenofovir and Entecavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
RS62434B1 (sr) 2014-12-26 2021-11-30 Univ Emory Antivirusni n4-hidroksicitidin derivati
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR20170003063A (ko) * 2015-06-30 2017-01-09 한미약품 주식회사 테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
JP6621933B2 (ja) 2015-11-09 2019-12-18 ギリアード サイエンシス インコーポレーテッド ヒト免疫不全ウイルスを処置するための治療組成物
JP2019513754A (ja) * 2016-04-08 2019-05-30 塩野義製薬株式会社 安定化した固形製剤
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
US10561614B2 (en) * 2017-01-27 2020-02-18 Steerlife India Private Limited Tenofovir granules
KR20200024259A (ko) 2017-06-30 2020-03-06 비이브 헬쓰케어 컴퍼니 조합물 및 이의 용도 및 치료
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN114126655A (zh) * 2019-07-03 2022-03-01 爱尔兰詹森科学公司 用利匹韦林治疗儿科患者的hiv的方法
CN112137981A (zh) * 2020-11-02 2020-12-29 成都晶富医药科技有限公司 富马酸丙酚替诺福韦片及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ250842A (en) 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030124186A1 (en) 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
KR20090053867A (ko) * 2003-01-14 2009-05-27 길리애드 사이언시즈, 인코포레이티드 복합 항바이러스 치료를 위한 조성물 및 방법
BRPI0514871A (pt) 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv cloridrato de 4-[[4-[[4-(2-cianoetenil)-2,6-dimetilfenil]amino]-2-pirimidi nil]amino] benzonitrila
KR101284361B1 (ko) 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007047371A2 (en) 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
AP2008004533A0 (en) 2005-12-14 2008-08-31 Cipla Ltd Pharmaceutical combination
PT2487163T (pt) * 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008143500A1 (en) 2007-05-22 2008-11-27 Ultimorphix Technologies B.V. Tenofovir disoproxil hemi-fumaric acid co-crystal
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
WO2009106960A2 (en) 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
AU2010210598B2 (en) 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy
ME02656B (me) 2009-09-21 2017-06-20 Gilead Sciences Inc 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje
WO2011077100A1 (en) 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
CN106511357A (zh) 2010-11-19 2017-03-22 吉利德科学公司 包含利匹韦林HCl和富马酸替诺福韦酯的治疗组合物

Also Published As

Publication number Publication date
AR084500A1 (es) 2013-05-22
CN103491948B (zh) 2016-11-02
JP2014500261A (ja) 2014-01-09
CN103491948A (zh) 2014-01-01
TW201238612A (en) 2012-10-01
PE20170521A1 (es) 2017-05-27
WO2012068535A1 (en) 2012-05-24
PE20140163A1 (es) 2014-02-08
AU2018202635A1 (en) 2018-05-10
MA34735B1 (fr) 2013-12-03
EP2826466A1 (en) 2015-01-21
EA201691695A1 (ru) 2017-11-30
HK1190064A1 (en) 2014-06-27
PL2640362T5 (pl) 2022-05-02
JP6138851B2 (ja) 2017-05-31
SG190333A1 (en) 2013-06-28
PT2640362E (pt) 2014-11-28
BR112013012245B1 (pt) 2022-09-27
SG10201509521WA (en) 2015-12-30
AP2013006931A0 (en) 2013-06-30
EP2640362A1 (en) 2013-09-25
ECSP13012700A (es) 2013-08-30
ZA201304481B (en) 2022-03-30
JP2015131853A (ja) 2015-07-23
EA025852B1 (ru) 2017-02-28
RS53691B1 (en) 2015-04-30
EP2640362B2 (en) 2021-12-01
EP2640362B1 (en) 2014-09-10
CA2818097A1 (en) 2012-05-24
AU2016208417B2 (en) 2018-04-05
HK1206592A1 (en) 2016-01-15
AP3816A (en) 2016-09-30
HRP20140946T1 (hr) 2015-02-13
AR123409A2 (es) 2022-11-30
US20130243857A1 (en) 2013-09-19
CL2013001402A1 (es) 2013-12-27
PE20211657A1 (es) 2021-08-24
ES2524408T3 (es) 2014-12-09
SG10201912527XA (en) 2020-02-27
SMT201400150B (it) 2015-01-15
NZ610729A (en) 2015-10-30
MX347512B (es) 2017-04-28
MX2013005669A (es) 2013-11-04
BR112013012245A2 (pt) 2016-08-09
UA114075C2 (xx) 2017-04-25
CA2818097C (en) 2019-07-30
CR20130293A (es) 2013-10-03
IL226300B (en) 2019-05-30
US10857102B2 (en) 2020-12-08
MY185604A (en) 2021-05-25
AU2011329642B2 (en) 2016-08-11
CN106511357A (zh) 2017-03-22
KR20140037799A (ko) 2014-03-27
DK2640362T3 (en) 2014-12-01
EA201390651A1 (ru) 2013-11-29
AU2011329642A1 (en) 2013-05-02
CO6761300A2 (es) 2013-09-30
TWI556840B (zh) 2016-11-11
KR101923103B1 (ko) 2018-11-28
DK2640362T4 (da) 2022-03-07
ECSP19078196A (es) 2019-11-30
ES2524408T5 (es) 2022-04-25
PL2640362T3 (pl) 2015-03-31
AU2016208417A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
AP3816A (en) Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
EP2891658A4 (en) PRODRUCE OF TENOFOVIR AND ASSOCIATED PHARMACEUTICAL USES THEREOF
EP2542086A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
ZA201404099B (en) Human notch receptor mutations and their use
ZA201300286B (en) Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfactase and uses thereof
PL2593095T3 (pl) (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania
HK1201454A1 (en) Therapeutic agents and uses thereof
GB2501611B (en) Alpha-2-macroglobulin compositions and therapeutic uses
PT2605757E (pt) Formulações à base de nalbufina e suas utilizações
EP2740728A4 (en) URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
EP2524215A4 (en) SURFACE NEUTRALIZATION OF APATIT
PL2521445T3 (pl) Preparat i jego zastosowanie
SG10201606161UA (en) Albumin Formulation and Use
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201011411D0 (en) Therapeutic compounds and their use
EP2694587A4 (en) PREPARATIONS OF BIOCOMPATIBLE POLYCAPROLACTONE FUMARATE
IL238461A0 (en) 1 hindole-3-carboxamide derivatives and their use as p2y12 inhibitors
HK1182712A1 (en) Therapeutic agents 976 976
SI2640362T1 (sl) Terapevtski sestavki, ki vsebujejo rilpivirin hcl in tenovofir disoproksil
IL229936B (en) Albumin formulation and use
EP2657236A4 (en) NEW 2-ALKYNYL-N9-PROPARGYLADENINE AND ITS MEDICAL USE
GB201012660D0 (en) Inhaler and formulation